AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

Drug Development

Clinical Catch-Up: March 23-27

Although some clinical trials are being slowed or halted, others are reporting out data. Here’s a look.

March 27, 2020

8 min read

Mark Terry

Drug Development

Biopharma Industry News for March 27: Update on the Novel Coronavirus

A summary of daily biopharma industry news. Please check out stories that are trending on March 27, 2020.

March 27, 2020

3 min read

BioSpace Editorial Staff

BioCapital

In Other (Biopharma) News: This Week’s Non-Coronavirus Stories

BioSpace takes a quick look at some recent, key industry news that is not related to the coronavirus.

March 25, 2020

4 min read

Alex Keown

Deals

AbbVie and Allergan Sign Divestiture Consent Decree with FTC, Move Closer to Finalizing Merger

The consent decree, including the proposed purchasers, remains subject to further review and approval by the Commissioners of the FTC.

March 18, 2020

2 min read

Alex Keown

Deals

M&A Boosts the Landscape of Efficiency in the Pharma Industry

Mergers and acquisitions in the pharmaceutical industry are not only a positive for the company that has made a bid for another company, but it is also good for the industry as a whole because of increases in efficiency across the entire field.

March 9, 2020

3 min read

Alex Keown

Deals

Allergan and AbbVie Turn Eyes to the FTC for Approval of their $63 Billion Merger

On Tuesday, the European Commission gave the green light to the merger following the divestiture of an investigational autoimmune treatment.

March 4, 2020

2 min read

Alex Keown

Deals

Consumer Groups, Unions Petition to Block Merger of Allergan and AbbVie

A group of unions and consumer organizations have banded together in opposition to the $63 billion merger citing concerns that it will create a monopoly and harm competition.

February 20, 2020

3 min read

Alex Keown

BioCapital

A Look at the Top 20 Most Expensive Drugs in the U.S.

These prices refer to the company’s list price. Most patients will not pay that price because of various forms of health insurance or patient assistance programs.

February 14, 2020

3 min read

Mark Terry